NO983911D0 - Alginatkapsler til bruk ved behandling av hjernesvulst - Google Patents

Alginatkapsler til bruk ved behandling av hjernesvulst

Info

Publication number
NO983911D0
NO983911D0 NO983911A NO983911A NO983911D0 NO 983911 D0 NO983911 D0 NO 983911D0 NO 983911 A NO983911 A NO 983911A NO 983911 A NO983911 A NO 983911A NO 983911 D0 NO983911 D0 NO 983911D0
Authority
NO
Norway
Prior art keywords
treatment
brain tumor
alginate capsules
alginate
capsules
Prior art date
Application number
NO983911A
Other languages
English (en)
Inventor
Rolf Bjerkvig
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Priority to NO983911A priority Critical patent/NO983911D0/no
Publication of NO983911D0 publication Critical patent/NO983911D0/no
Priority to RU2001107823A priority patent/RU2229287C2/ru
Priority to US09/763,682 priority patent/US6926888B1/en
Priority to NZ510167A priority patent/NZ510167A/en
Priority to BR9913326A priority patent/BR9913326A/pt
Priority to CNB998114332A priority patent/CN1191823C/zh
Priority to CA 2340325 priority patent/CA2340325A1/en
Priority to KR1020017002450A priority patent/KR100699286B1/ko
Priority to AU55389/99A priority patent/AU760433B2/en
Priority to IL14150199A priority patent/IL141501A0/xx
Priority to EP99941915A priority patent/EP1105100A1/en
Priority to TR200100583T priority patent/TR200100583T2/xx
Priority to JP2000567186A priority patent/JP2002523445A/ja
Priority to PCT/NO1999/000266 priority patent/WO2000012066A1/en
Priority to IL141501A priority patent/IL141501A/en
Priority to ZA200101464A priority patent/ZA200101464B/en
Priority to IS5855A priority patent/IS5855A/is
Priority to NO20010960A priority patent/NO20010960L/no
Priority to US11/104,245 priority patent/US20050180960A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
NO983911A 1998-08-26 1998-08-26 Alginatkapsler til bruk ved behandling av hjernesvulst NO983911D0 (no)

Priority Applications (19)

Application Number Priority Date Filing Date Title
NO983911A NO983911D0 (no) 1998-08-26 1998-08-26 Alginatkapsler til bruk ved behandling av hjernesvulst
PCT/NO1999/000266 WO2000012066A1 (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour
AU55389/99A AU760433B2 (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour
EP99941915A EP1105100A1 (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour
NZ510167A NZ510167A (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour
BR9913326A BR9913326A (pt) 1998-08-26 1999-08-25 Célula produtora encapsulada capaz de expressar uma molécula que seja um inibidor do desenvolvimento de tumor no cns, método para o tratamento de tumor do cns, e, uso de um alginato de imunoisolação
CNB998114332A CN1191823C (zh) 1998-08-26 1999-08-25 一种藻酸盐包囊的生产细胞
CA 2340325 CA2340325A1 (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour
KR1020017002450A KR100699286B1 (ko) 1998-08-26 1999-08-25 뇌 종양 치료용 알긴산염 캡슐
RU2001107823A RU2229287C2 (ru) 1998-08-26 1999-08-25 Альгинатные капсулы для применения в лечении опухоли мозга
IL14150199A IL141501A0 (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour
US09/763,682 US6926888B1 (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumor
TR200100583T TR200100583T2 (tr) 1998-08-26 1999-08-25 Beyin tümörü tedavisinde kullanılmak üzere aljinat kapsülleri.
JP2000567186A JP2002523445A (ja) 1998-08-26 1999-08-25 脳腫瘍治療用のアルギネートカプセル
IL141501A IL141501A (en) 1998-08-26 2001-02-19 Alginate capsules for use in the treatment of brain tumors
ZA200101464A ZA200101464B (en) 1998-08-26 2001-02-21 Alginate capsules for use in the treatment of brain tumour.
IS5855A IS5855A (is) 1998-08-26 2001-02-22 Algínat hylki til notkunar við meðferð á heilaæxli
NO20010960A NO20010960L (no) 1998-08-26 2001-02-26 Alginatkapsler til bruk ved behandling av hjernesvulster
US11/104,245 US20050180960A1 (en) 1998-08-26 2005-04-11 Alginate capsules for use in the treatment of brain tumour

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO983911A NO983911D0 (no) 1998-08-26 1998-08-26 Alginatkapsler til bruk ved behandling av hjernesvulst

Publications (1)

Publication Number Publication Date
NO983911D0 true NO983911D0 (no) 1998-08-26

Family

ID=19902361

Family Applications (2)

Application Number Title Priority Date Filing Date
NO983911A NO983911D0 (no) 1998-08-26 1998-08-26 Alginatkapsler til bruk ved behandling av hjernesvulst
NO20010960A NO20010960L (no) 1998-08-26 2001-02-26 Alginatkapsler til bruk ved behandling av hjernesvulster

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20010960A NO20010960L (no) 1998-08-26 2001-02-26 Alginatkapsler til bruk ved behandling av hjernesvulster

Country Status (16)

Country Link
US (2) US6926888B1 (no)
EP (1) EP1105100A1 (no)
JP (1) JP2002523445A (no)
KR (1) KR100699286B1 (no)
CN (1) CN1191823C (no)
AU (1) AU760433B2 (no)
BR (1) BR9913326A (no)
CA (1) CA2340325A1 (no)
IL (2) IL141501A0 (no)
IS (1) IS5855A (no)
NO (2) NO983911D0 (no)
NZ (1) NZ510167A (no)
RU (1) RU2229287C2 (no)
TR (1) TR200100583T2 (no)
WO (1) WO2000012066A1 (no)
ZA (1) ZA200101464B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319404C (en) * 1998-02-03 2014-01-07 Edwin W. Ades Recombinant lipidated psaa protein, methods of preparation and use
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
KR100969516B1 (ko) * 2007-08-16 2010-07-09 경북대학교 산학협력단 세포 생존력 및 기능을 향상시키는 도우넛형 세포 캡슐의제조 방법 및 세포 치료적용
US9555007B2 (en) 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5073491A (en) * 1988-12-23 1991-12-17 Hoffman-La Roche Inc. Immobilization of cells in alginate beads containing cavities for growth of cells in airlift bioreactors
US5459054A (en) * 1989-12-05 1995-10-17 Neocrin Company Cells encapsulated in alginate containing a high content of a- l- guluronic acid
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
JP4215273B2 (ja) * 1991-04-25 2009-01-28 ブラウン ユニヴァーシティ リサーチ ファンデーション 選択された治療物質放出用の移植可能で生体適合性の免疫遮断性ビークル
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
ES2125630T3 (es) 1994-07-08 1999-03-01 Baxter Int Dispositivo implantable que contiene celulas tumorales, para el tratamiento del cancer.
US6126936A (en) 1995-03-10 2000-10-03 Biohybrid Technologies Llc Microcapsules and composite microreactors for immunoisolation of cells
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
DE69725317T2 (de) 1996-04-03 2004-07-29 The Rogosin Institute Implantierbare agarose-kollagenkügelchen enthaltende zellen, die ein diffusionsfähiges biologisches produkt bilden und ihre verwendung
AU2674097A (en) * 1996-04-17 1997-11-07 Cytotherapeutics, Inc. Method and device for delivery of apoptosis-inducing molecules
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6368612B1 (en) * 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells

Also Published As

Publication number Publication date
NO20010960D0 (no) 2001-02-26
IL141501A0 (en) 2002-03-10
NO20010960L (no) 2001-04-25
RU2229287C2 (ru) 2004-05-27
IL141501A (en) 2006-10-31
JP2002523445A (ja) 2002-07-30
CN1320032A (zh) 2001-10-31
KR100699286B1 (ko) 2007-03-26
ZA200101464B (en) 2002-05-21
EP1105100A1 (en) 2001-06-13
BR9913326A (pt) 2001-05-15
KR20010074851A (ko) 2001-08-09
IS5855A (is) 2001-02-22
CN1191823C (zh) 2005-03-09
AU5538999A (en) 2000-03-21
US20050180960A1 (en) 2005-08-18
WO2000012066A1 (en) 2000-03-09
US6926888B1 (en) 2005-08-09
AU760433B2 (en) 2003-05-15
NZ510167A (en) 2003-09-26
TR200100583T2 (tr) 2001-06-21
CA2340325A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
ZA957483B (en) Compounds and methods for the treatment of cancer
EP1044002A4 (en) METHODS FOR THE TREATMENT OF HEART CONTRACTILITY
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
NO20005885L (no) Kombinasjonsterapi for behandling av refraktær depresjon
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
HK1041827B (zh) 用於治療***依賴性疾病的化合物以及製備和使用上述化合物的方法
EP1187604A4 (en) CONNECTIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS FAILURES
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
NO20020784D0 (no) Medikament for behandling av brudd
NO983911D0 (no) Alginatkapsler til bruk ved behandling av hjernesvulst
IL147410A0 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc
AU2566201A (en) Compounds and methods for the treatment of pain
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
GB2341099B (en) Clinical table for treatment of the spine
HK1040933A1 (zh) N-取代的氮雜二環烷衍生物在治療中樞神經系統疾病中的應用
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
KR100511819B1 (en) Compositions and Methods for the Treatment of Tumor
AU2420201A (en) Compounds and methods for the treatment of pain
KR100512820B1 (en) Compositions and Methods for the Treatment of Tumor
KR100526723B1 (en) Compositions and Methods for the Treatment of Tumor